Becker W, Schrell U, Buchfelder M, Hensen J, Wendler J, Gramatzki M, Wolf F
Department of Nuclear Medicine, University of Erlangen-Nuremberg, FRG.
Nuklearmedizin. 1995 Jun;34(3):100-3.
Neuroendocrine tumors with somatostatin receptor expression may be localized by 111In-octreotide scintigraphy. This study examines those thyroid conditions where 111In-octreotide uptake could be observed also in the thyroid gland. 26 consecutive patients who underwent 111In-octreotide scintigraphy for tumor localization were additionally examined for thyroid disease by sonography and 99mTc-pertechnetate scintigraphy. 12 of these patients had no significant thyroid uptake and had an euthyroid normal-sized thyroid gland 14 patients with 111In thyroid uptakes had endemic goiters, two of them with thyroid autonomy and one with Graves' disease. Thus, 111In-octreotide thyroid uptake was predominantly seen in patients with endemic goiter with or without thyroid autonomy.
表达生长抑素受体的神经内分泌肿瘤可通过铟-111奥曲肽闪烁扫描法进行定位。本研究调查了那些在甲状腺中也可观察到铟-111奥曲肽摄取的甲状腺疾病情况。对连续26例因肿瘤定位而接受铟-111奥曲肽闪烁扫描的患者，另外通过超声检查和锝-99m高锝酸盐闪烁扫描法检查甲状腺疾病。其中12例患者甲状腺摄取不显著，甲状腺大小正常且甲状腺功能正常；14例有铟-111甲状腺摄取的患者患有地方性甲状腺肿，其中2例有甲状腺自主性，1例患有格雷夫斯病。因此，铟-111奥曲肽甲状腺摄取主要见于有或无甲状腺自主性的地方性甲状腺肿患者。
